The Amici Curiosi – And other developments in Illumina/GRAIL

In this post, we share the latest developments in the Illumina/GRAIL merger. This case involves the now completed acquisition by Illumina of GRAIL, a company that has developed a test, which has shown the ability to detect multiple cancers from a single blood draw. GRAIL was founded by Illumina but spun off in 2016. Illumina … Continue reading The Amici Curiosi – And other developments in Illumina/GRAIL

Pay-for-delay hits 18 in the EU – Adulthood, but what comes next?

(...and four other takeaways from the Cephalon decision) Although the European Commission adopted the latest of its pay-for-delay decisions in November 2020, the Cephalon decision was only published in July of this year. With the Lundbeck agreements first coming under Commission scrutiny in 2003, pay-for-delay enforcement turned 18 this year. Below we set out a … Continue reading Pay-for-delay hits 18 in the EU – Adulthood, but what comes next?

Developments in antitrust enforcement in healthcare that caught our eye this summer

Excessive pricing, sham patents and private actions, please find below the antitrust enforcement developments in healthcare that caught our eye this summer. Three excessive pricing decisions and a statement of objections Are excessive pricing cases like London buses? You might think so after waiting for one for months only for four to appear practically at … Continue reading Developments in antitrust enforcement in healthcare that caught our eye this summer